Tesamorelin Research Guide
Tesamorelin complete guide: dosing, visceral-fat trial data, injection technique and side effects.
The visceral-fat GHRH analogue
Tesamorelin is a stabilised GHRH analogue and the only peptide in the class with FDA approval for reducing visceral adipose tissue, granted for HIV-associated lipodystrophy. Its trial data on visceral fat is the strongest in the GHRH group.
Dosing
The approved dose is 2 mg subcutaneously once daily, and research protocols commonly use 1–2 mg at bedtime. Rotate abdominal injection sites, since daily abdominal dosing over months is where site reactions accumulate.
IGF-1 monitoring
Tesamorelin raises IGF-1 more reliably than sermorelin does. Protocols running beyond twelve weeks generally include a baseline and follow-up IGF-1 to confirm levels stay within the age-adjusted reference range.
Cycle length and stacking
Twelve to twenty-four weeks is typical, because visceral-fat changes are measured over months. It is usually run alone or with ipamorelin rather than alongside a second GHRH analogue.
Frequently asked questions
What is the standard tesamorelin dose?
2 mg subcutaneously once daily is the approved dose; many research protocols use 1–2 mg at bedtime.
Does tesamorelin need bloodwork?
IGF-1 at baseline and during longer runs is the common monitoring approach, since tesamorelin raises IGF-1 more than milder GHRH analogues.
How long before visceral fat changes?
Trials measured meaningful visceral-fat reduction over 12 to 26 weeks, so multi-month runs are the norm.